Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Lukas Piazolo is active.

Publication


Featured researches published by Lukas Piazolo.


Journal of Chromatography B: Biomedical Sciences and Applications | 1996

Chromatographic and electrophoretic applications for the analysis of heparin and dermatan sulfate

Reinhard Malsch; Job Harenberg; Lukas Piazolo; Günther Huhle; Dieter L. Heene

Heparin and dermatan sulfate are highly sulfated polydisperse glycosaminoglycans. The methods to determine such compounds include chromatographic and electrophoretic techniques. Here we report on the performances of various analytical methods for the characterization and the determination of GAGs. Heparin, low-molecular-mass heparins, dermatan sulfate and low-molecular-mass dermatan sulfate were analyzed. High-performance size exclusion chromatography was used to determine the molecular mass, polydispersity, absorbance and the area under the absorbance-time curve. Polyacrylamide gel electrophoresis was used to determine the average molecular mass and the polydispersity. Heparin and dermatan sulfate preparations were analyzed by capillary electrophoresis using reversed polarity. The results obtained reflect different performances of various analytical methods used to characterize GAGs.


Hautarzt | 1997

Niedermolekulare Heparine Prophylaxe und Therapie thromboembolischer Erkrankungen

Job Harenberg; Günter Huhle; Lukas Piazolo; Reinhard Malsch

LerninhalteDer Wert der Thromboembolieprophylaxe in der perioperativen Medizin und in der inneren Medizin ist eindeutig belegt. Eine Unterlassung der Prophylaxe bei Patienten mit erhöhtem Thromboembolierisiko stellt einen Behandlungsfehler dar. Die Therapie der akuten tiefen Beinvenenthrombose muß stationär erfolgen. Die subkutane Verabreichung von konventionellem Heparin in hoher Dosierung und aPTT-adjustiert ist der kontinuierlichen intravenösen Dauerinfusion gleichwertig. Subkutanes hochdosiertes niedermolekulares Heparin ist möglicherweise zur Therapie der frischen tiefen Venenthrombose dem konventionellen Heparin überlegen. Die Heparin-induzierte Thrombozytopenie Typ II ist eine seltene aber schwerwiegende Nebenwirkung. Maßnahmen zur Früherkennung dieser Nebenwirkungen gibt es nicht. Die Therapie besteht in einem Wechsel der Antikoagulation auf nicht heparinhaltige Antikoagulantien.


Cytometry | 1996

Analysis of Heparin Binding to Human Leukocytes Using a Fluorescein-5-Isothiocyanate Labeled Heparin Fragment

Job Harenberg; Reinhard Malsch; Lukas Piazolo; Günter Huhle; Dieter L. Heene

The binding of LMWH-tyr-FITC to granulocytes, monocytes, and lymphocytes was analyzed by flow cytometry using a low-molecular-weight heparin (LMWH) labeled with fluorescein-5-isothiocyanate (FITC). FITC was covalently bound to tyramine, which was synthesized to LMWH by endpoint-attachment (Malsch et al.: Anal Biochem 217:255-264, 1994). The binding was rapid, specific, dose-dependent, saturable, and reversible. To investigate the molecular weight dependence of heparins, heparin-derived di- to dodecasaccharides were used. With decreasing molecular weight, the amount of oligosaccharides increased; these were bound to granulocytes, monocytes, and lymphocytes (r = -0.77). The degree of sulfation of non-heparin glycosaminoglycans influenced the binding to leukocytes. Decreasing the degree of sulfation decreased the binding. The pentasaccharide did not bind as strongly as the other heparin-derived oligosaccharides, indicating an AT III-independent mechanism. Two classes of heparin binding sites were identified on granulocytes and one class of binding sites on monocytes and lymphocytes. The lowest amount of LMWH-tyr-FITC detected was 1 ng on granulocytes, 0.18 ng on monocytes and 0.01 ng on lymphocytes. The data suggest that heparin and other sulfated polysaccharides may play a role in the physiology of thrombosis, arteriosclerosis, and inflammation by binding to granulocytes, monocytes, and lymphocytes.


Archive | 1996

Intact Biological Activity and Binding to Granulocytes of LMM-Heparin-Tyramine-Fitc

Lukas Piazolo; Job Harenberg; Reinhard Malsch; Dieter L. Heene

Unfractionated and low molecular mass heparins are widely used for prophylaxis and treatment of venous thromboembolism (1–3). The biologic activities and the pharmacodynamic properties of heparins are quite well understood. However, direct measurement of their concentration encounters different problems. The radioactive labeling of heparins using the substitution with 3-(4-Hydroxyphenyl)-propionic-acid-N-hydroxy-succimideester may alter polysaccharide backbone. The binding of fluorescent compounds to heparin leads to a lipophilic character and also alter the polysaccharide backbone if a specific binding has not been used. Recently, we have reported on the endpoint attachment of fluorescein-5-isothyo-cianate (Fitc) to a low molecular mass heparin-tyramine. Fitc has been bound to tyramine, which has been coupled by endpoint attachment to the terminal anhydromannose group of LMM-Heparin (4, 5). This technique should provide an intact binding site of the LMM-Heparin to the binding sequences on proteins. Beside the anticoagulant activity, many non-anticoagulant activities of heparin are of clinical relevance (6). These may be induced by the binding of heparin to the endothelium, erythrocytes or monocytes (7–9).


Archive | 1996

Binding of Glycosaminoglycans to Leukocytes Using Fluorescent Labeled Gag-Derivatives

Job Harenberg; Reinhard Malsch; Lukas Piazolo; Günter Huhle; Dieter L. Heene

The non-anticoagulant properties of glycosaminoglycans (GAGs) include antithrombotic, antiatherosclerotic, antiinflammatory and antimetastatic actions and are thought to be caused by binding of the GAGs to positively charged groups of matrices and peptides (1, 2, 3). Heparins are the best known group of GAGs and they are linear polysaccharide chains with defined negatively charged sulfate and carboxylic groups. Fractions and fragments of heparins and heparin-derived oligosaccharides were obtained to investigate the metabolism and the structure function relationship with plasma and cellular proteins. Binding of heparin and heparin fragments to human endothelial cells was demonstrated using radiolabeled compounds (4). Decreasing the molecular weight of the heparin chains, the binding to endothelial cells decreased (5). Heparin has been reported to bind to human monocytes and to modulate their procoagulant activity (5). Blood macrophages were found to internalize and degrade heparin (6). Unfractionated heparin seems to bind to erythrocytes as demonstrated using radioactively labeled compound (7).


Archive | 1996

Inequivalence of Glycosaminoglycans Using High-Performance Size Exclusion Chromatography, Polyacrylamide Gel Electrophoresis and High-Performance Capillary Electrophoresis

Reinhard Malsch; Job Harenberg; Lukas Piazolo; Dieter L. Heene

Biologically active sulfated polysaccharides like heparin and dermatan sulfate are commonly known GAGs (1)* Although its primary application as anticoagulant heparin can be considered as polyelectrolytic drug displaying a variety of biological activities. Heparins can be easily neutralized in vitro and in vivo by an equigravimetric amount of protamine or polybrene.


Seminars in Thrombosis and Hemostasis | 1997

Long-Term Anticoagulation of Outpatients with Adverse Events to Oral Anticoagulants Using Low-Molecular-Weight Heparin

Job Harenberg; Günter Huhle; Lukas Piazolo; Christina Giese; Dieter L. Heene


Seminars in Thrombosis and Hemostasis | 1997

Anticoagulation in Patients with Heparin-Induced Thrombocytopenia Type II

Job Harenberg; Günter Huhle; Lukas Piazolo; Lianchun U. Wang; Dieter L. Heene


Thrombosis and Haemostasis | 2003

Anti-hirudin antibodies alter pharmacokinetics and pharmacodynamics of recombinant hirudin

Karl-Georg Fischer; Volker Liebe; Renata Hudek; Lukas Piazolo; Karl K. Haase; Martin Borggrefe; Günter Huhle


Seminars in Thrombosis and Hemostasis | 2001

Effect of Thrombin Inhibitors and a Glycoprotein IIb/IIIa Receptor Antagonist in an Ex Vivo Human Experimental Thrombosis Model

Kaweh Zokai; Lukas Piazolo; Job Harenberg

Collaboration


Dive into the Lukas Piazolo's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Giangiacomo Torri

Federal University of Paraná

View shared research outputs
Researchain Logo
Decentralizing Knowledge